These findings indicate that the functional medial parietal gradients are a robust measure that can be used to detect subtle changes associated with AD and could potentially be used as an alternative imaging marker for very early disease stages since the observed gradient changes reflect a biomarker profile that is associated with an increased risk of developing AD (higher p-tau/tau and lower Aß). The gene discussed is MAPT; the disease is Alzheimer disease.